Skip to main content
Thursday 21 May 2026
BlueSky linkedin youtube
header links
  • Get Newsletters
  • Media Kit
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Equity and Sustainability
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • GLP-1
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • Spotlight on
    • ASCO
    • BIO-Europe
    • C-Suite Innovators
    • ESMO
    • Frontiers Health
    • JP Morgan
    • Global Policy Insights
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
youtube linkedin BlueSky
Sign in

Disease spotlight: LHON

Views & Analysis
santhera header 16x9
Image
pharmaphorum editor
profile-mask
pharmaphorum Editor
26 January, 2018
FacebookXLinkedin

R&D
Why UCB bet a billion dollars on cell therapy for epilepsy

Why UCB bet a billion dollars on cell therapy for epilepsy

UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png
Digital
Discover a new era of healthcare panel engagement
Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Deep Dive
Why pharma needs honest patient dialogue

Why pharma needs honest patient dialogue

Astellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the patient experience.

R&D
Lucid white paper visual
Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D
hVIVO Future of RSV research
Sponsored

Rethinking clinical research: The case for human challenge t...

Sales & Marketing
HCP using smart phone
Sponsored

What HCPs Say Pharma Gets Wrong About Survey Research

Most market researchers already know the standard rules: keep surveys concise, write clear questions, and reduce unnecessary respondent burden.

R&D
Emerging Trends in Personalised Medicine at PHARMAP 2026
Partner Content

Emerging Trends in Personalised Medicine at PHARMAP 2026

The Pharmaceutical Manufacturing & Packaging Congress is an exclusive annual event that fosters networking and knowledge-sharing among professionals

R&D
5th mRNA-Based Therapeutics Summit Europe
Partner Content

5th mRNA-Based Therapeutics Summit Europe

The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines

 
 

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Category : Views & Analysis /

Editor's Picks

  1. BMS signs $15.2bn R&D alliance with China's Hengrui
  2. UK Health Secretary resigns, sparking leadership speculation
  3. Reports: Makary out, Diamantas in as FDA commissioner
  4. EU agrees plan to tackle essential medicine shortages
  5. Clock starts ticking on UK's single patient record plan
News
Lilly's 'triple G' retatrutide aces crucial obesity trial

Lilly's 'triple G' retatrutide aces crucial obesity trial

Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png
Digital
Discover a new era of healthcare panel engagement
Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • Axtria Ignite 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Get Newsletters

 
 
youtube linkedin BlueSky
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company